The very thorough fairly detailed article by Insid
Post# of 153871
(Total Views: 511)
Posted On: 03/29/2021 10:43:32 PM
The very thorough fairly detailed article by Insider Financial today, surprisingly IMO, favors leronlimab over HGEN and RLFTF.
What might seriously hold HGEN back in the future is the perception that is that it’s just a one hit wonder and not much of a platform drug. It has an ongoing Phase 2/3 study in Graft versus Host Disease (GvHD), but it really doesn’t stand a chance in that indication if CYDY’s drug leronlimab gets approval. Based on the MOA and efficacy a leronlimab approval will displace lenzilumab, so HGEN shareholders need to be prepared for the worst and might want to consider trimming into any more strength above $30 or hedge their bet by buying CYDY which has a more powerful platform technology and many more catalysts in the coming future.
https://insiderfinancial.com/covid-stocks-pop...ta/181209/
What might seriously hold HGEN back in the future is the perception that is that it’s just a one hit wonder and not much of a platform drug. It has an ongoing Phase 2/3 study in Graft versus Host Disease (GvHD), but it really doesn’t stand a chance in that indication if CYDY’s drug leronlimab gets approval. Based on the MOA and efficacy a leronlimab approval will displace lenzilumab, so HGEN shareholders need to be prepared for the worst and might want to consider trimming into any more strength above $30 or hedge their bet by buying CYDY which has a more powerful platform technology and many more catalysts in the coming future.
https://insiderfinancial.com/covid-stocks-pop...ta/181209/
(2)
(0)